Pharmaceutical and biotechnology companies developing active pharmaceutical ingredients (APIs) must balance development costs, product quality, regulatory requirements, intellectual property protection, and long-term manufacturing needs. For sponsors advancing a molecule toward an Investigational New Drug (IND) application, these considerations influence early development decisions and the selection of a contract development and manufacturing organization (CDMO).
Olon USA combines U.S.-based process chemistry, analytical development, and API manufacturing with the technical expertise and manufacturing capacity of Olon S.p.A.’s global network. This model gives North American sponsors direct access to U.S. technical teams while providing additional options for cost optimization, technology transfer, and commercial production across international sites.
The combination is particularly relevant for sponsors seeking to retain U.S. manufacturing capabilities without limiting their programs to the resources of a single facility.
Olon USA Combines U.S. Expertise With Global Manufacturing Resources
Olon operates a global network of 14 manufacturing sites across the United States, Europe, and Asia. The network brings together specialized scientific expertise, chemical manufacturing capabilities, and production capacity to support pharmaceutical development and manufacturing programs.
Olon USA’s primary differentiators include its U.S.-based process chemistry and analytical teams, direct communication with North American sponsors, expanding domestic manufacturing capabilities, and access to the broader Olon network. These resources allow the company to develop and optimize synthetic processes in the United States while evaluating how international facilities can contribute to intermediate production, specialized technical requirements, or commercial scale-up.
The Concord, Ohio, site also provides a practical geographic advantage. Its operating costs can be more competitive than those of some higher-cost U.S. manufacturing locations, while its location supports communication with North American clients during their regular business hours. Sponsors can work directly with local technical and supply chain teams without coordinating every discussion across international time zones.
For projects requiring additional manufacturing capacity or specific intermediate chemistry, Olon can evaluate a model in which materials are produced at qualified facilities in Europe or India before final API processing in the United States. This approach can help balance manufacturing costs with domestic production objectives.
The ability to coordinate these activities within one organization distinguishes Olon USA from a standalone manufacturing site. Sponsors can access U.S.-based development and production alongside the expertise and infrastructure of a global CDMO.
Supporting API Development From IND-Enabling Work Through Commercialization
Early decisions in API development can affect product quality, manufacturing efficiency, regulatory readiness, and the cost of later-stage production. Olon USA’s process chemistry and analytical teams work together to evaluate synthetic routes, improve yields, optimize manufacturing processes, and identify and control impurities in intermediates and final APIs.
This work supports the development of processes that can meet the requirements of clinical manufacturing and, where appropriate, progress toward commercial production. Analytical scientists help characterize impurities and establish suitable controls, while process chemists assess the chemistry and manufacturing conditions needed to produce the target molecule consistently.
The team can also draw on expertise elsewhere in the Olon network when a project requires specialized analytical testing or technical capabilities not available at the Concord site. Cross-site collaboration and knowledge sharing allow scientists to apply relevant experience to individual programs.
For emerging biotechnology companies, these capabilities can be especially important. Development budgets may depend on achieving milestones such as IND submission and successful completion of early clinical studies. An inadequately characterized impurity or an insufficiently developed manufacturing process can introduce additional work, costs, and regulatory complications.
Sponsors can reduce these risks by selecting a CDMO that evaluates process chemistry, analytical requirements, and future manufacturing needs early in development. Olon USA’s experience in API development and risk reduction for innovative molecules supports this focus on evaluating technical challenges and manufacturing requirements before they affect later development milestones.
Planning for Commercial API Manufacturing From the Start
A process suitable for early clinical supply may require further optimization before it can support commercial demand. Sponsors must consider production volumes, process efficiency, raw material availability, manufacturing capacity, and the requirements of target markets.
Olon USA works with clients to optimize synthetic routes and evaluate how processes can transition to larger production scales. Its development and manufacturing capabilities support programs from early process work through clinical supply and commercial production, subject to the specific requirements of each project.
When additional capacity or specialized production capabilities are needed, the wider Olon network can provide further options. A process developed in the United States may be transferred to another Olon site for larger-scale manufacturing, while a program requiring domestic production can explore using internationally manufactured intermediates for final processing in the United States.
Olon also offers technology transfers between its sites without an additional technology-transfer fee to the client, according to the company’s stated approach. This can provide sponsors with greater flexibility when evaluating where individual manufacturing steps should occur.
Integrating development and manufacturing planning helps preserve process knowledge, limit unnecessary handoffs, and address commercial requirements before they become constraints.
U.S. Manufacturing and Global Sourcing Support Supply Resilience
Manufacturing location has become an important consideration for pharmaceutical companies planning long-term API supply. Geopolitical uncertainty, transportation disruptions, changing trade conditions, and raw material availability can affect manufacturing costs and supply continuity.
Olon USA provides a domestic manufacturing option backed by international production resources. Its supply chain and logistics teams work with sponsors to evaluate raw material sourcing and coordinate the movement of materials across manufacturing locations.
The global network can support strategies that combine international intermediate production with U.S.-based final API manufacturing. This gives sponsors an opportunity to evaluate domestic production without automatically relocating every step of the manufacturing process to the United States.
The approach also helps companies assess geographic diversification and potential dual-sourcing strategies. Where technically and regulatorily appropriate, qualified manufacturing sites may provide additional flexibility if production requirements change or a supply disruption affects one location. Alternative sites must be assessed and qualified for the specific product and process; access to a global network does not automatically establish a second qualified source.
These considerations are particularly important for sponsors preparing for commercial supply, when production interruptions can affect customer commitments and product availability. Olon USA’s global API manufacturing network and supply-chain capabilities provide additional context for evaluating manufacturing options and supply continuity.
Protecting Intellectual Property and Maintaining Quality Standards
For companies developing proprietary molecules, intellectual property protection is a significant consideration when selecting a CDMO. Sponsors need confidence that their process information, technical documentation, and confidential development data will be protected throughout the relationship.
Olon USA emphasizes the protection of client intellectual property, supported by U.S.-based development and manufacturing operations. Sponsors can work directly with the technical team responsible for their program while drawing on additional expertise across the Olon organization when needed.
Quality and regulatory capabilities also support this model. Olon operates within a shared global quality framework, helping align expectations and facilitate collaboration between sites. The wider organization has regulatory personnel who can support sponsors as they navigate applicable requirements for API development and manufacturing.
For sponsors considering a technology transfer or a manufacturing strategy involving multiple facilities, quality oversight, documentation, process knowledge, and clear accountability remain essential. Each proposed manufacturing location must be evaluated against the relevant product, process, and regulatory requirements.
The objective is to give sponsors access to a broader set of manufacturing options while maintaining appropriate controls over product quality, confidential information, and regulatory obligations.
Expanded U.S. Capabilities Support High-Potency and Commercial Programs
Olon USA has invested in expanding its Concord manufacturing capabilities to meet demand for U.S.-based API production. The site’s development and manufacturing infrastructure supports a wider range of project requirements, including specialized handling of highly potent compounds and increased production capacity.
The high-potency API suite provides a contained environment for development and manufacturing activities involving compounds that require stringent exposure controls. These capabilities are relevant to oncology programs, targeted therapies, and other applications involving highly potent APIs.
Sponsors can learn more about the site’s high-potency API manufacturing and containment capabilities, including how specialized infrastructure supports the handling of compounds that require strict occupational exposure controls.
The broader expansion of the Concord site also strengthens its role in U.S. commercial API manufacturing. Additional capacity and investment support the site’s continued development from an operation historically known for research, process development, and early-stage manufacturing into a more integrated U.S. development and commercial manufacturing hub.
The investment in expanded U.S. API manufacturing capacity in Concord, Ohio reflects Olon USA’s response to evolving client requirements for domestic production, scalability, and supply flexibility.
Together, these investments give sponsors more options for U.S.-based development and production, backed by the resources of an international manufacturing organization.
A Technology Transfer Demonstrates the Value of Global Collaboration
A project involving a major European pharmaceutical company illustrates how Olon USA and the wider Olon network can work together to address changing manufacturing requirements.
The sponsor sought to establish a U.S. manufacturing footprint for an API program in response to evolving geopolitical considerations and domestic supply priorities. Olon coordinated the technology transfer to its Concord, Ohio, facility, combining existing process knowledge with investment in U.S. manufacturing infrastructure to bring the process into production.
The project required coordination across technical and manufacturing teams, alongside significant capital investment and facility construction. It demonstrates how Olon can combine global process expertise with U.S.-based manufacturing capabilities to help sponsors establish domestic production.
For pharmaceutical companies considering a similar strategy, the appropriate approach depends on process complexity, technical readiness, facility requirements, manufacturing capacity, and applicable quality and regulatory obligations. Olon’s integrated network can support technology transfer between sites, helping sponsors evaluate manufacturing options while maintaining coordination across development and production activities.
The project highlights a key differentiator for Olon USA: the ability to combine local execution with global technical expertise, manufacturing resources, and infrastructure investment to address specific client requirements.
One CDMO Partner for Development, Manufacturing, and Supply Planning
Managing multiple CDMOs and suppliers can require sponsors to coordinate separate project teams, technical documentation, quality systems, timelines, and manufacturing strategies. These responsibilities can create additional complexity for smaller biotechnology companies with limited internal CMC resources.
Olon USA offers North American sponsors a direct point of contact supported by the capabilities of Olon S.p.A. The relationship allows sponsors to discuss process development, analytical requirements, manufacturing location, technology transfer, and future supply needs within a connected organization.
The global network can also provide options for sourcing intermediates, accessing specialized expertise, and evaluating production at other sites as a program advances. Shared quality expectations and cross-site collaboration support coordination, while the appropriate manufacturing strategy remains specific to each molecule and project.
For sponsors, the primary value is not simply access to multiple facilities. It is the ability to evaluate development and manufacturing decisions together, with U.S.-based technical support and a global organization available to help address changing program requirements.
Start a Conversation With Olon USA About Your API Program
Choosing an API development and manufacturing partner requires an assessment of scientific expertise, process quality, intellectual property protection, manufacturing capacity, and long-term supply requirements. Olon USA combines U.S.-based process chemistry, analytical development, and expanding manufacturing capabilities with the resources of Olon S.p.A.’s global network.
Whether a program requires IND-enabling development, clinical supply, process optimization, high-potency API capabilities, technology transfer, or a strategy for commercial manufacturing, Olon USA can work with sponsors to assess the technical and operational requirements.
Contact Olon USA to start a conversation about your API development or manufacturing project and explore how its U.S. capabilities and global network can support your program from development through commercial supply.